AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients

Using MRI techniques, we show here that normalization of tumor vessels in recurrent glioblastoma patients by daily administration of AZD2171—an oral tyrosine kinase inhibitor of VEGF receptors—has rapid onset, is prolonged but reversible, and has the significant clinical benefit of alleviating edema...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Batchelor, Tracy T., Sorensen, A. Gregory, di Tomaso, Emmanuelle, Zhang, Wei-Ting, Duda, Dan G., Cohen, Kenneth S., Kozak, Kevin R., Cahill, Daniel P., Chen, Poe-Jou, Zhu, Mingwang, Ancukiewicz, Marek, Mrugala, Maciej M., Plotkin, Scott, Drappatz, Jan, Louis, David N., Ivy, Percy, Scadden, David T., Benner, Thomas, Loeffler, Jay S., Wen, Patrick Y., Jain, Rakesh K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2007
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2748664/
https://ncbi.nlm.nih.gov/pubmed/17222792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2006.11.021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados